The firm’s revenue from biosimilars grew 25% in the
latest quarter.
| Photo Credit:
DHIRAJ SINGH
Biocon expects a 50% drop in costs for
developing complex biosimilars as the United States has proposed
to ease clinical testing for the drugs that make up more than
60% of its revenue, a top executive said on Wednesday.
Biosimilars are copies of costlier biological drugs used
to treat major illnesses such as cancer, rheumatoid arthritis,
psoriasis and diabetes. The U.S. Food and Drug Administration
last month proposed to simplify drug testing by lowering the
requirement for large comparative clinical efficacy trials.
Biocon, which aims to cumulatively launch 20 biosimilars by
2030, is focusing on upcoming launches in the key markets of
U.S. and Europe, Shreehas Tambe, CEO of Biocon Biologics, a unit
of Biocon, said in an interview.
“You can do more because it’s (FDA’s draft proposal) going
to halve the cost of development … you can develop them
(biosimilars) and bring them to patients faster and make it more
affordable.”
Biocon, which has seven of its biosimilars in the commercial
market in the U.S., is looking to launch two more in the next
six months. The company’s oncology biosimilar medicines have a
fourth of the U.S. market share and will benefit from the lower
development cost, Tambe said.
The firm’s revenue from biosimilars grew 25% in the
latest quarter.
Biocon is also looking to expand its generics segment with
the launch of weight-loss drugs to drive future growth, the
company had said earlier.
Published on November 13, 2025
